



HAL
open science

Recent Progress in Genome Editing for Gene Therapy Applications: The French Perspective

Mario Amendola, Aurélie Bedel, Ana Buj-Bello, Mathieu Carrara, Jean-Paul Concordet, Giacomo Frati, David Gilot, Carine Giovannangeli, Alejandra Gutierrez-Guerrero, Marine Laurent, et al.

► **To cite this version:**

Mario Amendola, Aurélie Bedel, Ana Buj-Bello, Mathieu Carrara, Jean-Paul Concordet, et al.. Recent Progress in Genome Editing for Gene Therapy Applications: The French Perspective. *Human Gene Therapy*, 2021, 32 (19-20), pp.1059-1075. 10.1089/hum.2021.191 . hal-03420183

HAL Id: hal-03420183

<https://hal.science/hal-03420183>

Submitted on 27 Nov 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Review article**Recent progress in genome editing for gene therapy applications: the French perspective**

Mario Amendola^{1,2}, Aurélie Bedel^{3,4,5}, Ana Buj-Bello^{1,2}, Mathieu Carrara⁶, Jean-Paul Concordet⁶, Giacomo Frati^{7,8}, David Gilot⁹, Carine Giovannangeli⁶, Alejandra Gutierrez-Guerrero¹⁰, Marine Laurent^{1,2}, Annarita Miccio^{7,8}, François Moreau-Gaudry^{3,4,5}, Célia Sourd^{1,2}, Julien Valton¹¹ and Els Verhoeyen^{10,12,*}.

Affiliations:

¹Genethon, 91000, Evry, France

²Université Paris-Saclay, Univ Evry, Inserm, Genethon, Integrare research unit UMR_S951, 91000, Evry, France

³Bordeaux University, France.

⁴INSERM U1035, Biotherapy of genetic diseases, inflammatory disorders and cancers, Bordeaux, France.

⁵University Hospital Bordeaux, Biochemistry Laboratory, France

⁶Museum National d'Histoire Naturelle, Inserm U1154, CNRS UMR 7196, Sorbonne Universités, Paris, France

⁷Laboratory of chromatin and gene regulation during development, Imagine Institute, INSERM UMR1163, 75015, Paris, France

⁸ Université de Paris, 75015, Paris, France

⁹Inserm U1242, Université de Rennes, France, Centre de lutte contre le cancer Eugène Marquis, Rennes, France.

¹⁰CIRI – International Center for Infectiology Research, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, Ecole Normale Supérieure de Lyon, Université Lyon, F-69007, Lyon, France

¹¹Cellectis. SA, 75013 Paris, France.

¹²Université Côte d'Azur, INSERM, C3M, 06204 Nice, France

***Correspondance to:**

Els Verhoeyen: CIRI, Université de Lyon; INSERM U1111; ENS de Lyon; Université Lyon1; CNRS, UMR 5308, 69007 Lyon, France/Université Côte d'Azur, INSERM, C3M, 06204 Nice, France. (els.verhoeyen@ens-lyon.fr/els.verhoeyen@unice.fr)

Running title (50 characters): Genome editing for gene therapy in France

Keywords (6): Genome editing, CRISPR/Cas9, gene therapy, HSCs, gene editing toxicity, T cell

Abstracts (300 words)

Recent advances in genome editing tools, especially the novel developments in the clustered regularly interspaced short palindrome repeats associated protein (CRISPR/Cas)-derived editing machinery have revolutionized not only basic science but, importantly, also the gene therapy field. Their flexibility and ability to introduce precise modifications in the genome in order to disrupt or correct genes or insert expression cassettes in safe harbors in the genome underlines their potential applications as a medicine of the future to cure many genetic diseases. In this review, we give an overview of the recent progress made by French researchers in the field of therapeutic genome editing while putting their work in the general context of advances made in the field. We focus on recent hematopoietic stem cell gene editing strategies for blood diseases affecting the red blood cells or blood coagulation as well as lysosomal storage diseases. We report on a genome editing based therapy for a muscular dystrophy and the potency of T cell gene editing to increase anti-cancer activity of chimeric antigen receptor (CAR) T cells to combat cancer. We will also discuss technical obstacles and side-effects such as unwanted editing activity that need to be surmounted on the way towards a clinical implementation of genome editing. We propose here improvements developed today, including by French researchers to overcome the editing related genotoxicity and improve editing precision by the use of novel recombinant nuclease-based systems such as nickases, base editors and prime editors. Finally, a solution is proposed to resolve the cellular toxicity induced by the systems employed for gene editing machinery delivery.

Introduction

Gene or genome editing: the basics

Gene editing is a type of genetic engineering where nucleotides or bigger DNA sequences are either inserted, deleted or replaced in the genome using nucleases, which create site-specific double-strand breaks (DSB) in genomic loci. There are different types of nucleases: Meganucleases (MGNs), transcription activator-like effector nucleases (TALENs), zinc fingers nucleases (ZFNs) and clustered regularly interspaced short palindromic repeats associated to Cas9 nucleases (CRISPR/Cas9). The cellular machinery repairs the DSB induced by these nucleases either by non-homologous end joining pathways (Non-Homologous or Microhomology-Mediated End Joining, NHEJ or MMEJ) or by homology-directed repair (HDR) when a DNA template encoding sequences that are homologous to the targeted genomic locus is available. The most frequent DNA repair pathway that takes place after DSB is NHEJ. In this case DNA ends are fused without a repair template and this leads to insertion or deletion of nucleotides, often introducing frameshift mutations, totally or partially blocking gene transcription and translation.¹ MMEJ is also frequently involved in repair of DSBs induced by Cas9 and typically results in deletions flanked by short stretches of microhomology that may be predicted for highly efficient disruption of the target open reading frame. In contrast, HDR results in gene correction/insertion by homologous recombination with the sister chromatid or delivery of a donor DNA repair template. The DSB induced by endonucleases at a specific locus can be sealed by HDR when an exogenous DNA template is provided carrying homology arms to the targeted genomic locus. This template is provided either by plasmids, integration-deficient lentiviral vectors (IDLVs), recombinant adeno-associated viruses serotype 6 (rAAV6) or by electroporation of double stranded DNA or oligonucleotides (ODN).^{2,3} However, since HDR is restricted to the S/G2 phase of the cell cycle, gene modification remains a challenge for the scientific community, in particular in primary gene therapy target cells.

One type of these nucleases, the bacteria-originated CRISPR/Cas9 system has revolutionized the methodology to produce knock-out and knock-in genome editing due to its high specificity, activity, easy design and highly efficient gene editing in cell lines and primary cells.⁴ The CRISPR/Cas9 component can be introduced in the cell of interest using different methods, e.g. by using CRISPR/Cas9 encoding retroviral vectors⁵ or plasmids⁶ and RNAs³ encoding these components introduced by electroporation. Currently though, the method of choice to obtain efficient gene editing in primary human T and B cells and hematopoietic stem and progenitor cells (HSPCs) is electroporation of ribonucleoproteins (RNPs), incorporating

1
2
3 guide RNA(s) (gRNA) and Cas9 proteins.⁷ In contrast to retroviral delivery, RNP delivery
4 offers a major advantage since the Cas9/gRNAs are only transiently present in the cell, thereby
5 avoiding insertional mutagenesis and cellular toxicity related to persistent Cas9 activity⁸,
6 implying a safety benefit essential for clinical applications.
7
8
9

10 11 12 13 **Therapeutic gene editing** 14

15
16
17 The multiple advantages of gene editing over gene addition in the gene therapy field are: 1) the
18 capacity of modifying/correcting specific endogenous DNA sequences; 2) the normal
19 transcriptional regulation of the gene is maintained since correction can be introduced at the
20 targeted genomic locus thus allowing a spatio-temporal and thus physiological regulation of
21 transgene expression² and 3) the insertional mutagenesis risks and the activation of oncogenes
22 are strongly reduced. Thus, precise genetic manipulation of cells by gene editing provides
23 unprecedented opportunities for correction of immune-deficiencies such as X-linked severe
24 combined immunodeficiency (SCID-X1)⁹ or Wiskott-Aldrich syndrome (WAS)¹⁰ or bone
25 marrow failures, such as Fanconi Anemia (FA) and many other disease indications.¹¹ HSPC-
26 based gene therapy is very attractive treatment for FA because corrected stem cells have a
27 selective advantage.¹² Interestingly, NHEJ was utilized to create an insertion/ deletion (indel)
28 next to an FA mutation leading to correction of FA phenotype at high efficiency.¹³
29
30
31
32
33
34
35
36
37
38

39 Additionally, β -hemoglobinopathies (β -thalassemia and sickle cell disease) are attractive
40 targets for therapeutic gene-editing using HDR.¹⁴ However, NHEJ might offer alternative
41 correction strategies for gene therapy of β -thalassemia and Sickle cell disease. Gene editing
42 strategies for β - hemoglobinopathies have rather focused on disruption of silencing factors/
43 regulators such as BCL11A in hematopoietic stem cells (HSCs) to induce *de novo* expression
44 of fetal hemoglobin.^{15,16} In this review, two collaborating French research teams will extend
45 further on the more recent gene editing approaches for correction of hemoglobinopathies but
46 also other monogenetic diseases such as blood clotting diseases and lysosomal storage
47 disorders.
48
49
50
51
52
53

54 In addition to HSCs, T cells are very powerful gene therapy target cells and are highly amenable
55 to gene editing. Gene editing in T cells is being used currently to generate potent chimeric
56 antigen receptor (CAR) T cells for combating cancer.¹⁷ CARs are laboratory designed T cell
57 signaling receptors which upon encounter with a cancer specific antigen will get activated and
58
59
60

1
2
3 eliminate the cancer cells. One example for improving CAR T cell design is gene editing
4 mediated knock-out of the endogenous T cell receptor (TCR) to avoid the graft-versus-host
5 disease. This might permit to produce a universal CAR T cell.¹⁸ This allows to move away from
6
7 the up to now obligatory costly autologous CAR T cell therapies for treatment of cancer
8
9 patients. We will focus in this review on some of the newest gene editing strategies employed
10
11 by a French research team to improve CAR T cell efficiency.
12
13

14
15 Interestingly, not only hematopoietic cells such as T, B and HSCs are gene therapy targets for
16 gene editing but recently a French team has developed a gene editing approach to correct a type
17 of muscle disease¹⁹. They will report in this review on Myotonic Dystrophy type 1 (DM1)
18 correction via gene editing of a gene that is mainly expressed in smooth, skeletal, and cardiac
19 muscles. For the French gene therapy landscape and beyond it is also important to underline
20 that quite recently the Technological Research Accelerator in Genomic Therapy (ART-TG)
21 was put in place to help the gene therapy labs in France to conduct preclinical studies and to
22 manufacture products and materials in GMP for clinical trials which will include gene editing
23 protocols (<https://www.art-tg.com/about-us>).
24
25
26
27
28
29
30
31
32

33 **Cellular and genomic toxicity induced by genome editing tools**

34
35

36 Genomic toxicity caused by gene editing nucleases remains a major safety concern in
37 therapeutic applications since they can introduce unwanted DSBs in non-targeted DNA
38 sequences of the genome called 'off-targets'. The off-target activity is linked to areas of the
39 genome which share high homology with the specific site targeted for gene editing.²⁰ When an
40 off-target cutting event occurs, it can be repaired via the NHEJ and MMEJ pathways,
41 potentially resulting in an indel mutation; or, if it occurs simultaneously with an on-target or a
42 second off-target cutting event, the off-target cutting activity can generate a chromosomal
43 rearrangement. In this review, we are not focusing on detection or prediction of off-target
44 effects for gene editing but refer to an excellent recent review.²¹
45
46
47
48
49
50

51 To increase the precision of gene editing and reducing off-target cuts, other CRISPR genome
52 editing tools are continuously developed, with enhanced targeting scope, and improved editing
53 specificity. Three main classes of CRISPR-based genome editing agents are available today,
54 namely, nucleases as mentioned above, base editors and prime editors. Base editors generate
55 single-nucleotide changes in DNA, while prime editors use Cas9 fused to an engineered reverse
56
57
58
59
60

1
2
3 transcriptase, programmed with a prime editing guide RNA (pegRNA) that both specifies the
4 target site and encodes the desired sequence edit template.²⁰ In this review French researcher
5 discuss strategies designed to increase the efficiency of precise gene editing by HDR and finally
6 base editing and prime editing, which represent improved alternative tools for precise gene
7 editing applications in gene therapy.
8
9

10
11 As mentioned above off-target modifications by the CRISPR/Cas9 first-generation nuclease
12 have been widely reported. However, the on-target NHEJ genotoxicity in response to DNA
13 DSBs has often been underestimated and is not well studied yet. This can lead to huge
14 chromosomal deletions or rearrangements and is not well understood up to now.^{22,23} Therefore,
15 a French research team will dedicate here a section to CRISPR/Cas9 induced on-target genomic
16 toxicity by presenting their recent work from a French team elaborating on how to resolve these
17 unwanted side-effects.
18
19

20
21 Finally, the different delivery systems such as stable retroviral gene transfer and electroporation
22 of plasmids encoding the gene editing tools, induce still cellular toxicity.^{10,24} This is
23 problematic when we want to gene modify primary human T, B and HSCs since it is clear now
24 that a minimum of living modified cells needs to be reinfused in the patient for therapeutic
25 efficiency. Improved protocols for delivery of CRISPR/Cas9 with the associated gRNAs by
26 electroporation of RNPs have reduced cellular toxicity to some extent. In this review, a French
27 team will elaborate on new delivery tools for the gene editing machinery, which especially
28 avoids cell death in primary gene therapy target cells.
29
30
31
32
33
34
35
36
37
38
39
40

41 **Recent developments in genomic editing for gene therapy**

42 **Novel genome editing approaches for β -hemoglobinopathies**

43
44
45 β -hemoglobinopathies are caused by mutations affecting the production of the β -globin chain
46 of the adult hemoglobin tetramer (Hb) (**Figure 1A and B**). In particular, sickle cell disease
47 (SCD) is caused by a single nucleotide mutation in the sixth codon of the β -globin gene, which
48 leads to the E6V amino acid substitution. Hemoglobin tetramers containing the defective sickle
49 β^S -globin (HbS) polymerize under hypoxia, and red blood cells (RBCs) assume a sickle shape
50 and become inflexible (**Figure 1A**). Sickle RBCs have a short half-life and obstruct micro
51 vessels causing a chronic multi-organ disease associated with poor quality of life and short life
52
53
54
55
56
57
58
59
60

1
2
3 expectancy. β -thalassemia is caused by mutations that reduce (β^+) or abrogate (β^0) β -globin
4 production. The uncoupled α -globin chains precipitate, causing apoptosis of erythroid
5 precursors and hemolytic anemia (**Figure 1B**). Transplantation of autologous, genetically
6 modified hematopoietic stem cells (HSCs) is an attractive therapeutic option for patients
7 lacking a suitable allogeneic HSC donor.
8
9

10
11
12 The clinical severity of β -hemoglobinopathies is alleviated by the co-inheritance of
13 mutations causing fetal β -like γ -globin expression in adult life - a benign condition termed
14 hereditary persistence of fetal Hb (HPFH).²⁵ γ -globin exerts a potent anti-sickling effect in
15 SCD and compensates for β -globin deficiency in β -thalassemia.
16
17

18
19 Two classes of HPFH mutations have been described, large deletions in the β -globin
20 locus or mutations in the γ -globin promoters. HPFH deletion mutations are large deletions
21 usually encompassing the adult β - and δ -globin genes. They are thought to either remove γ -
22 globin inhibitory sequences or to juxtapose the γ -globin genes ($G\gamma$ and $A\gamma$) to distal
23 transcriptional enhancers (**Figure 1C**). HPFH mutations in the two γ -globin promoters cluster
24 in the -200, -175 and -115 regions upstream of the transcriptional start sites. They are mainly
25 point mutations or small deletions or insertions that either disrupt the binding sites (BS) of fetal
26 Hb (HbF) repressors (e.g., LRF and BCL11A in position -200 and -115, respectively) or
27 generate BS for transcriptional activators (e.g., KLF1, TAL1 and GATA1 in position -200, -
28 175 and -115, respectively).
29
30

31
32 We have recently generated a 13.6-kb HPFH-like large deletion in the β -globin locus
33 using the CRISPR/Cas9 nuclease system in primary HSPCs from SCD patients (**Figure 1C**).¹⁵
34 NHEJ-mediated deletion of the 13.6-kb region led to a robust reactivation of HbF synthesis in
35 the erythroid progeny of edited HSPCs and to a substantial amelioration of the sickling cell
36 phenotype. Interestingly, HbF reactivation upon generation of HPFH-like deletions in adult
37 erythroid cells was associated with increased interaction of the γ -globin promoters with potent
38 enhancers located within the β -globin locus. Furthermore, we compared the efficiency of
39 different methods to deliver the CRISPR/Cas9 system into HSPCs and generate HPFH-like
40 deletions. RNP delivery exhibited a good balance between cytotoxicity and efficiency, while
41 minimizing the off-target activity.²⁶
42
43

44
45 Furthermore, we have used the CRISPR/Cas9 RNP complexes to disrupt the LRF or
46 BCL11A repressor BS in the γ -globin promoters by NHEJ and microhomology-mediated end
47 joining (MMEJ) inducing Indel generation, thus mimicking the effect of HPFH mutations
48 (**Figure 1C**).²⁷ In primary SCD patient-derived HSPCs, the efficient targeting of LRF or
49 BCL11A BS resulted in a high proportion of γ -globin expressing HSPC-derived RBCs and
50
51
52
53
54
55
56
57
58
59
60

1
2
3 correction of the sickling cell phenotype. Editing efficiency was minimal at the vast majority
4 of the predicted off-target sites. Importantly, xenotransplantation of HSPCs treated with gRNAs
5 disrupting the LRF or BCL11A BS in immunodeficient NOD/SCID/ γ c^{-/-} mice showed a high
6 editing efficiency in long-term repopulating HSCs.
7
8
9

10 Overall, these studies identified several genomic sites in the β -globin locus as potent
11 targets for genome-editing treatment of SCD. Interestingly, this strategy can be potentially
12 applied also to β -thalassemia.
13
14

15 To further improve the efficacy of HSC editing-based therapy for β -thalassemia, we
16 have devised a novel gene replacement strategy. Clinical data have shown that the severity of
17 β -thalassemia directly correlates with the number of α -globin (*HBA*) genes, with deletions of
18 *HBA* genes having a beneficial effect for patients.²⁸ In addition, CRISPR/Cas9-mediated
19 downregulation of α -globin genes expression ameliorated the globin balance in β^+ -thalassemia
20 patients.²⁹ To treat both β^0 - and β^+ -thalassemia, we successfully combined the expression of a
21 therapeutic β -like globin chain and the down-regulation of α -globin expression (**Figure 1D**).⁸
22 In particular, we used CRISPR/Cas9 RNP containing a gRNA targeting the 2 identical 5'UTRs
23 of the α -globin genes ($\alpha 1$ and $\alpha 2$) to delete the $\alpha 2$ -globin allele that was replaced via HDR by
24 a therapeutic β -like globin gene (delivered using AAV6). Editing of HSPCs from β -thalassemia
25 patients led to correction of the α/β globin imbalance. Xenotransplantation experiments in
26 immunodeficient NOD/SCID/ γ c^{-/-} mice showed long-term repopulating capacity of edited
27 HSCs *in vivo*. These results were already confirmed by an independent group, validating the
28 robustness of this editing approach.³⁰
29
30
31
32
33
34
35
36
37
38
39
40
41

42 **Advances in genome editing approaches for systemic diseases**

43 Enzyme replacement therapy (ERT) consists in the periodic intravenous administration
44 of specific enzymes produced to supplement a protein that is deficient because of a genetic
45 defect. ERT is approved or under investigation to treat more than 40 inherited disorders, mostly
46 involving blood factors and lysosomal enzymes. Although life saving for some patients this
47 requires frequent costly injections with a peak-and-trough serum kinetics, which reduce
48 patients' compliance to the therapy and efficacy of treatment. Sometimes these therapies are
49 affected by development of antibodies against the administered drugs, which negatively
50 influence drug bioavailability and activity. Instead, gene therapy can provide constant serum
51 levels of therapeutic proteins with a single treatment and can induce immune tolerance to the
52 expressed transgene.^{31,32} Autologous HSCs can be successfully engineered *ex vivo* by LV to
53
54
55
56
57
58
59
60

1
2
3 express a transgene of interest; however, the semi-random integration pattern is intrinsically
4 associated with the risk of inactivating an oncosuppressor and transactivating an oncogene.
5 Targeting a selected genomic harbour can reduce insertional mutagenesis risk, as also enables
6 the exploitation of endogenous promoters, or selected chromatin contexts, to achieve specific
7 transgene expression levels/patterns.³³
8
9

10
11 We recently identified the α -globin as a suitable locus for CRISPR/Cas9-mediated
12 targeted gene addition. The idea is to combine the strong transcriptional output of the α -globin
13 promoter with the abundance of transgene-expressing erythroblasts to maximize protein
14 production, reducing the number of integration events required to reach therapeutic levels. In
15 addition, the α -globin locus is a safe harbour, since there are 4 α -globin genes per cell (**Figure**
16 **1 D**) and the loss of up to 3 α -globin alleles is mostly asymptomatic.¹⁴ We edited human HSPCs
17 with an RNP complex combining Cas9 with a gRNA targeting the 5' UTR of the α -globin genes
18 (**Figure 1D**). The therapeutic transgenes were delivered with an AAV6 vector and integrated
19 via the HDR pathway. We first demonstrated that the selected gRNA provided efficient and
20 precise editing without affecting viability and differentiation potential of HSPCs and
21 hemoglobin expression in HSPC-derived erythroid cells or inducing off-target genome
22 modifications. Then, we demonstrated that the expression of the integrated transgene was
23 specific to the erythroid lineage and was induced during erythroid differentiation, mimicking
24 the endogenous α -globin physiological expression pattern. In addition, we tested this strategy
25 with therapeutic transgenes for different monogenic diseases, such as hemophilia B and
26 lysosomal storage disorders (LSD).¹⁴
27
28
29
30
31
32
33
34
35
36
37
38

39 Hemophilia B is a coagulation disorder caused by the absence of functional Factor IX
40 in the blood. We demonstrated that targeted integration in HSPCs of a F9 gene under the control
41 of the HBA2 promoter resulted in FIX mRNA expression and protein secretion in their
42 erythroid progeny and that secreted FIX was functional in reducing blood clotting time *in vitro*.
43
44
45

46 LSD are inherited metabolic conditions characterized by an abnormal build-up of toxic
47 metabolites in lysosomes as a result of enzyme deficiencies. Wolman disease (WD) in particular
48 is a life-threatening genetic condition due to the accumulation of cholesterol and triglycerides
49 caused by mutations in the gene encoding lysosomal acid lipase (LAL). We demonstrate that
50 LAL secreted from erythroid cells derived from edited HSPCs was functional and capable of
51 cross-correcting patient's cells *ex vivo*, reducing both toxic cholesterol and lipid accumulations.
52 Finally, we confirmed that edited HSCs conserve their *in vivo* homing, engraftment and multi-
53 lineage potential by performing xenotransplantation experiments in immunodeficient
54 NOD/SCID/ γ c^{-/-} mice.¹⁴ Overall, we established a safe and versatile CRISPR/Cas9-based HSC
55
56
57
58
59
60

platform for different therapeutic applications, including haemophilia and inherited metabolic disorders.

Genome editing as a valid option to treat neurological disorders

Microsatellite repeat expansion (MRE) diseases are a group of at least 50 inherited disorders with unmet medical need due to a pathological increase in the number of short tandem nucleotide repeats within the coding or non-coding region of the causative genes. Most of these diseases affect the central nervous system or the neuromuscular system, such as fragile X syndrome (FXS), Huntington disease (HD), Friedreich ataxia (FRDA), spinocerebellar ataxias (SCAs), spinal and bulbar muscular atrophy (SBMA), amyotrophic lateral sclerosis/frontotemporal dementia (C9-ALS/FTD) and myotonic dystrophies (DM1 and DM2).³⁴ Gene editing strategies to correct pathological nucleotide repeat expansions at the DNA or RNA level have been investigated for some of these disorders during the past years.³⁵ Here we provide an overview on the approaches that have been explored for myotonic dystrophy type 1 (DM1), with a particular focus on the work performed by our laboratory. DM1, also known as Steiner's disease, is the most prevalent form of muscular dystrophy in adults with a global incidence of about 1 in 8000 individuals. It is a multisystemic autosomal dominant disorder caused by a CTG repeat expansion in the 3' untranslated region (3' UTR) of the *DMPK* gene.³⁶ The number of *DMPK* CTG repeats ranges from 51 to several thousands in affected individuals, correlates with disease severity and inversely with age of onset, and increases during successive generations. Clinical manifestations include myotonia, muscle weakness, respiratory insufficiency, cardiac arrhythmias, gastrointestinal symptoms, somnolence, diabetes and cataracts. Premature death occurs generally due to cardiovascular disease, sudden death and respiratory insufficiency.³⁷ The disease mechanism has been extensively studied in animal models and results from a toxic gain of function of *DMPK* RNA transcripts containing expanded CUG repeats, which accumulate in the nucleus as stable ribonucleoprotein aggregates named foci, leading to defects in the alternative splicing of many pre-mRNAs.³⁸ Early attempts to correct CAG/CTG repeat expansions at the genomic level were performed using meganucleases, ZNFs and TALENs in various cell types, the latter appearing more efficacious and specific in inducing repeat contractions, at least in yeast models. TALENs were also used to insert a premature polyA signal upstream of *DMPK* CTG repeats in DM1 induced

1
2
3 pluripotent stem cells (iPSCs) resulting in transcripts without repeats.^{39,40} With the emergence
4 of the CRISPR/Cas system as a powerful gene-editing tool, the potential of this technology to
5 treat MRE disorders was revealed using a CRISPR/Cas9 D10A nickase in a reporter cellular
6 model demonstrating its ability to induce CAG/CTG repeat contractions.⁴¹ Later, several
7 CRISPR/Cas-based therapeutic strategies targeting various regions of the *DMPK* gene or
8 transcripts were evaluated in cellular and mouse models of DM1, opening new perspectives for
9 the treatment of this disorder.^{19,42-46}

10 Our team developed a dual viral vector strategy to excise the pathogenic *DMPK* CTG repeat
11 region by co-expression of the small sized *Staphylococcus aureus* Cas9 (SaCas9) and selected
12 pairs of guide RNAs targeting genomic sequences surrounding the trinucleotide repeats.¹⁹ This
13 approach was initially tested in cultured DM1 patient-derived myoblasts carrying a large CTG
14 repeat expansion (2600 CTG repeats) to evaluate the ability of the CRISPR/Cas9 system to
15 delete large expansions, which resulted in the disappearance of nuclear foci and correction of
16 splicing abnormalities in edited cells. Based on these promising results, we further expanded
17 our work in a DMSXL disease mouse model, which contains a human *DMPK* transgene with
18 ~1200 CTG repeats, by intramuscular administration of serotype 9 adeno-associated viral
19 (AAV9) vectors expressing CRISPR/SaCas9 components and established the proof-of-concept
20 that genome excision of a large CTG expansion is also feasible *in vivo* in skeletal muscle.
21 Injection of AAV9 vectors in tibialis anterior muscle of homozygous DMSXL mice was able
22 to reduce the overall amount of myonuclei with toxic *DMPK* RNA foci but also showed some
23 limitations. Therefore, additional preclinical studies will be required to further optimize and
24 evaluate the therapeutic benefit and safety of this approach at the level of the whole body by
25 targeting the entire musculature, including heart, and eventually other tissues affected in the
26 disease.

27 **Advanced genome editing strategies to unleash the full potential of CAR T cells**

28
29 The adoptive transfer of CAR T cells represents a highly promising strategy to fight
30 against multiple cancer indications. This strategy relies on the engineering of T cells to redirect
31 their cytolytic activity toward malignant cells via transgenic expression of a tumor antigen-
32 specific receptor at their surface. Today, the current protocols of treatment consist in autologous
33 adoptive T cell transfer. In this approach, T lymphocytes recovered from patients, are
34 genetically modified, and expanded *ex vivo* before infusion back into patients. Clinical results
35 gathered over more than 10 years show impressive rates of complete remission in different

1
2
3 indications.⁴⁷ These highly positive clinical outcomes led to the FDA-approval of 4 different
4 products named tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel and
5 lisocabtagene maraleucel to treat acute lymphoblastic leukemia, large B cell lymphoma, mantle
6 cell lymphoma and multiple myeloma, respectively.⁴⁸⁻⁵⁰
7
8
9

10 While highly promising, autologous CAR T-cell therapies have been hampered by many
11 practical and clinical challenges. Practical challenges include the production time and high cost,
12 the dependence on patients T-cells' fitness that is reduced by the disease or previous lines of
13 therapies and the logistical conundrum associated to the coordination of CAR T-cell production
14 and injection. Clinical challenges include the life threatening cytokine storm observed in most
15 patients⁵¹, the transient persistence of CAR T-cell fitness and their difficult access to tumor. It
16 also includes the tumor-dependent inhibitory signals and tumor-associated suppressor cells that
17 are usually found in the microenvironment of tumors and contribute, directly or indirectly, to
18 the impairment of CAR T-cell antitumor activity.
19
20
21
22
23
24

25 These multiple challenges cannot be easily addressed with standard cell engineering
26 methods. However, implementation of advanced gene editing technologies in cell culture
27 processes brought a wealth of solutions that are now revolutionizing the field of CAR T-cell
28 therapies and more broadly, immunotherapies. The following section describes how gene
29 editing technologies, especially those based on TALEN, could be leveraged to overcome some
30 of the practical and clinical challenges faced by CAR T-cell therapies.
31
32
33
34
35

36 One of the first important challenge tackled by gene editing technologies was to enable
37 the production of universal CAR T-cell compatible with adoptive transfer in allogeneic settings.
38 In contrast to the autologous approach, universal CAR T-cell could be mass produced from
39 healthy donor T-cells and can then be theoretically transferred as an off-the-shelf medicine to
40 any HLA-mismatched patients (**Figure 2A and 2B**, respectively). However, for this approach
41 to be successful, the graft versus host (GvH) and the host versus graft (HvG) reactions must be
42 avoided to safely allow CAR T-cells to engraft and express their antitumor function in HLA-
43 mismatched patients (**Figure 2C** top panel). Indeed, in this scenario, GvH reaction would
44 consists in the recognition of the Major Histocompatibility Complex (MHC) marker exposed
45 at the surface of host cells by an alloreactive $\alpha\beta$ T-cell receptor ($\alpha\beta$ TCR) exposed on the CAR
46 T-cell surface. This recognition would promote an acute, non specific and globale depletion of
47 host tissues and lead to an eventual fatal outcome (**Figure 2C**). HvG reaction would involve
48 the same recognition mechanism but results in the depletion of CAR T-cell by alloreactive host
49 T-cells and thus lead to a poor antitumor activity and therapeutic outcome. Thus, without
50
51
52
53
54
55
56
57
58
59
60

1
2
3 additional genome engineering, adoptive transfert of CAR T-cell in allogeneic settings would
4 be simply unsafe and inefficient.
5

6 In the past 10 years, several different genome engineering strategies were developed to
7 prevent GvH and HvG. The first strategy developed to prevent GvH and HvG was to engineer
8 a $\alpha\beta$ TCR and CD52 double knocked out (KO) CAR T-cell through TALEN-mediated gene
9 inactivation. $\alpha\beta$ TCR inactivation was shown to be highly efficient and to robustly prevent GvH.
10 In addition, CD52 inactivation enabled CAR T-cell to resist to alemtuzumab, an FDA-approved
11 antibody designed to bind and promote depletion of CD52 expressing immune cells.⁵² Such
12 resistance enabled Alemtuzumab-dependent host lymphodepletion led to an efficient
13 prevention of HvG and created a receptive environment for $\alpha\beta$ TCR/CD52-deficient CAR T-
14 cell engraftment in the clinic. ⁵³ A second strategy consisted in the TALEN-mediated
15 inactivation of $\alpha\beta$ TCR and dCK, which enabled to produce $\alpha\beta$ TCR deficient CAR T-cells
16 resistant to purine nucleotide analogues (PNAs, including fludarabine clofarabine and
17 decitabine) that are commonly used to lymphodeplete patients prior CAR T-cell infusion
18 (**Figure 2C**, middle panel).⁵⁴ A third strategy aimed at inactivating $\alpha\beta$ TCR along with B2M to
19 create $\alpha\beta$ TCR/MHC deficient CAR T-cells (**Figure 2C**, right panel). This approach enabled
20 the generation of non-alloreactive CAR T-cell capable of evading alloreactive T-cell attack and
21 is currently evaluated in clinic to assess its safety and efficacy profile.
22
23
24
25
26
27
28
29
30
31
32
33

34 Genome engineering technics were also used to mitigate the cytokine release syndrome
35 (CRS) associated to CAR T-cell infusion. CRS is characterized by fever, hypotension and
36 respiratory insufficiency and is correlated to elevated pro-inflammatory cytokines in patients'
37 following CAR T-cell infusion. Its severity is mainly mediated by IL-6, IL-1 and other factors
38 produced by patient macrophages, that are commonly activated in the vicinity of CAR T-cell.⁵⁵
39 Two independent studies^{56,57} identified Granulocyte-macrophage colony-stimulating factor
40 (GMCSF) as one of the main mediators of macrophage activation by CAR T-cell (**Figure 2D**,
41 left panel), opening opportunities to mitigate CRS through genome engineering of CAR T-cell.
42 In that context, TALEN- and CRISPR/Cas9-mediated inactivation of GMCSF in CAR T-cells
43 was shown to drastically decrease CAR T-cell dependent-secretion of GMCSF and to abolish
44 subsequent macrophage-dependent secretion of multiple CRS biomarkers, including IL-6
45 (**Figure 2D**, right panel). While this approach may not fully eliminate CRS symptoms, it could
46 be combined with other engineering approaches and improve the overall safety of CAR T-cell
47 therapies for cancer patients.⁵⁸
48
49
50
51
52
53
54
55
56
57

58 Finally genome engineering was also used to improve CAR T-cell antitumor function
59 in the hostile tumor microenvironment. For instance, among the multiple strategies published
60

1
2
3 in the past years, one consisted in rewiring PD1 expression into the secretion of a powerful
4 immunostimulatory agent named IL-12 (**Figure 2E**).⁵⁸ This was achieved by inserting an IL-
5 12 expression cassette in frame with the PD1 gene using a PD1-specific TALEN and an AAV6
6 matrix bearing the IL-12 expression cassette. This strategy resulted in the inactivation of PD1,
7 one of the main actor of tumor-dependent inhibition of CAR T-cell and in the localized and
8 tumor-dependent secretion of IL-12. This approach improved antitumor activity and
9 proliferation capacity of CAR T-cell while mitigated the risks of adverse events commonly
10 observed when IL-12 is systemically infused in patients.⁵⁹
11
12
13
14
15
16
17
18
19

20 **Toxicity and recent improvements in gene editing for gene therapy**

21 **ON-target genotoxicity in gene therapy target cells upon CRISPR/Cas9 nuclease** 22 **challenge**

23
24 CRISPR/Cas9 is a powerful technology for genome editing. However, high efficiency of the
25 editing nuclease is not void of downsides due to unwanted and uncontrolled activity. The most
26 studied and almost resolved side effect is OFF-target genotoxicity. By contrast, the ON-target
27 genotoxicity of CRISPR/Cas9 nuclease due to DNA DSB at the targeted locus has received
28 little attention and is still underestimated. Using Cas9 nuclease-induced DSB at the
29 Uroporphyrinogen III Synthase (*UROS*) locus (chromosome 10q) to model and correct
30 congenital erythropoietic porphyria (CEP), we demonstrated that HDR is rare compared with
31 the competitive unwanted NHEJ pathway. Indeed, the edition is often bi-allelic, and
32 uncontrolled small indels are concomitant to precise correction. They lead to disrupted targeted
33 sequences and cause unwanted dysfunctional protein in cell lines and iPSC.^{60,61} We
34 demonstrated that uncontrolled indels induced by the NHEJ are very frequent in corrected
35 HEK293T, with a precise genome editing ratio (HDR/NHEJ) of 0.5. Several approaches have
36 been proposed to improve this ratio e.g. by NHEJ inhibition or activating the HDR pathways
37 (for review see Sledinski et al. ⁶²). It is also possible to exploit the design of the gRNA. We
38 tested an original approach to correct compound heterozygous recessive mutations. We
39 compared editing efficiency and genotoxicity using a biallelic gRNA *versus* a mutant allele-
40 specific gRNA in iPSCs derived from a CEP patient carrying compound heterozygous *UROS*
41 mutations. We reported that, unlike the biallelic one, the mutant allele-specific gRNA was free
42 of ON-target collateral damage and allows a precise gene correction without concomitant indels
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 in the same iPSC clone. This design that avoids genotoxicity with ON-target scarless gene
4 correction should be recommended for recessive diseases with frequent cases of compound
5 heterozygous mutations.⁶¹
6
7

8 In addition to small indels, a single ON-target DSB (without a second DSB at OFF-
9 target genomic loci) can also lead to interstitial large deletions of several kilobases, symmetrical
10 or not at the targeted site, in mouse hematopoietic progenitors, in human immortalized
11 differentiated cells or in mouse embryos.⁶³ Recently, larger deletions (up to three hundred
12 kilobases) in mouse zygote were reported.⁶⁴
13
14
15
16

17 Unexpectedly, even larger genomic rearrangements may occur. We reported that
18 CRISPR/Cas9 can cause megabase-scale chromosomal terminal truncations targeting *UROS*
19 (Chromosome 10q) in two human cell lines (HEK-293T and K562) and in human primary
20 fibroblasts deficient for the tumor suppressor p53. This megabase-scale deletion was mapped
21 by array-CGH (comparative genomic hybridization). This by-product starts at DSB cut site and
22 deletes the chromosomal end (7.5 Mb). It removes 43 genes including five proto-oncogenes
23 and seven tumor suppressors.⁶⁰ This risk of inducing Megabase-scale deletions was recently
24 confirmed in other human primary cell-types (iPSC and human embryos)^{65,66}, suggesting that
25 CRISPR-mediated large rearrangements are not locus or cell-type dependent.
26
27
28
29
30
31
32

33 We then evaluated if unexpected large rearrangements can occur targeting globin genes
34 for gene editing (important gene therapy targets for hemoglobinopathies as described above) in
35 chromosome 11p. Again, we observed that genome editing targeting globin genes induces
36 megabase-scale losses of heterozygosity (LOH) from the globin CRISPR/Cas9 cut site to the
37 telomere (5.2Mb). In established lines, CRISPR/Cas9 nuclease induced frequent (up to 20%)
38 terminal chromosome 11p truncations and rare copy-neutral LOH (without loss of genomic
39 material). Targeting the β -globin cluster in primary HSPCs, we detected 1.1% of clones (7/648)
40 with acquired megabase LOH induced by CRISPR/Cas9. In-depth analysis by CGH/SNP-array
41 revealed the presence of copy-neutral LOH from the cut site to the telomere without deletion.
42 So, the cell-type seems to be crucial to determine the type of DNA rearrangement that might
43 occur after CRISPR/Cas9 DSB. In HSPCs, copy-neutral (CN) LOH led to 11p15.5 partial
44 uniparental disomy, comprising two Chr11p15.5 imprinting centers (*H19/IGF2:IG-DMR/IC1*
45 and *KCNQ1OT1:TSS-DMR/IC2*) and impacting *H19* and *IGF2* expression (Boutin et al.,
46 Nature Com; 2021, in press). It is possible that CN-LOH is a survival repair response to the
47 loss of an allele in p53-proficient cells. The mechanism of extra-large terminal CN-LOH post
48 CRISPR/Cas9-mediated DSB is probably consistent with Break-induced replication (BIR)
49 recently described in eukaryotic cells. It involves extensive DNA synthesis from the DSB to
50
51
52
53
54
55
56
57
58
59
60

1
2
3 the telomere. It can even provoke chromothripsis, an extensive and complex chromosome
4 rearrangement restricted to the chromosome targeted by CRISPR-Cas9.⁶⁷ In parallel, interstitial
5 smaller kilo-base CN-LOH by gene conversion in the close surroundings of the DSB was also
6 described in the globin cluster.⁶⁸
7
8
9

10 This ON-target genotoxicity, at base/kilobase and megabase-scale could be a safety
11 concern for CRISPR clinical trials and has to be confirmed in other gene *loci* and *in vivo*
12 settings. These new data highlight the necessity to develop preclinical tests to evaluate carefully
13 not only the well-known OFF-target but also the ON-target genotoxicity risks. Further studies
14 to understand the mechanisms of the appearance of these extra-large chromosomal
15 rearrangements will be necessary to find solutions/alternatives to prevent them. Interestingly,
16 nickases, inducing a DNA single strand break, allow HDR without indels or truncations in cell
17 lines.⁶⁰ Unfortunately, its use is still challenging for clinical studies due to low efficiency in
18 human primary cells. Modulating DSB DNA repair pathways or developing clinical trials with
19 DSB-free genome editing are currently under study. Novel and safer gene editing strategies and
20 tools are also mentioned in the next section.
21
22
23
24
25
26
27
28
29

30 **Improving gene editing precision: the safer DNA repair perspective**

31
32
33
34 The goal of genome editing experiments is to change a targeted DNA sequence into a desired
35 DNA sequence in the genome of cultured cells or organisms. In most cases, especially in gene
36 therapy approaches aimed at precise gene correction or gene insertion as exemplified in the first
37 section, a single sequence product is pursued at high efficiency. However, in some applications,
38 heterogeneous edited sequences may be acceptable; for example it is the case in gene therapy
39 approaches developed in by some French teams to treat SCD and β -thalassemia by disruption
40 of binding sites for transcriptional repressors in HBG promoters mimicking HPFH mutations
41 (²⁷ and see above) and we can also cite diseases such as Huntington disease or DM1, caused by
42 trinucleotide expansions that can be reduced or deleted by targeting the repeats with CRISPR
43 nucleases as shown by us and the GF Richard lab at the Pasteur Institute in Paris.⁶⁹ Improved
44 CRISPR genome editing tools are continuously evolving, with enhanced targeting scope,
45 improved editing specificity and importantly, enhanced precision of genome editing activity,
46 which are all important issues when clinical applications are envisioned. Three main classes
47 of CRISPR-based genome editing agents are available today, namely, nucleases, base editors
48 and prime editors, expanding the solutions that can be chosen and optimized for a given genome
49 editing application. We discuss in this section strategies designed to increase the efficiency of
50
51
52
53
54
55
56
57
58
59
60

1
2
3 precise gene editing by HDR and finally base editing and prime editing, which are promising
4 alternative tools for precise gene editing in gene therapy.
5

6 The basic principle of precise gene editing in living cells was first pioneered with the I-Sce1
7 nuclease isolated by the Dujon lab (Pasteur Institute, Paris). Together with several other groups,
8 they used I-Sce1 to introduce a targeted double strand break into a model gene carrying the 16
9 pb I-Sce1 target sequence and strongly stimulated precise gene modification by homology-
10 dependent repair (HDR)⁷⁰, triggering the new era of gene editing with programmable nucleases.
11 ZNF, TALEN and CRISPR/Cas9 were next used to target genomics sites of interest and more
12 recently, successive generations of programmable nucleases were engineered providing even
13 greater flexibility and easy use for precise gene editing based on HDR. End-joining pathways
14 of DNA DSB repair, however, were found to generally prevail over HDR in mammalian cells.
15 Hence, precise modification by HDR, copying from template DNA with the desired sequence
16 change, is not the most common outcome and imprecise modifications are generally much more
17 frequent (⁷¹ and see the above section). Therefore, approaches to improve genome editing
18 precision are actively explored.
19

20 Different types of donors can be used as homology templates, single-stranded or double-
21 stranded DNA. HDR pathways differ depending on the nature of donor DNA, and are broadly
22 classified into homologous recombination (HR) for double-stranded donors and single-stranded
23 templated repair (SSTR) for single-stranded donors, that likely share early HDR steps but
24 require different factors necessary for downstream incorporation of donor information.⁷²
25 Importantly, this expands the possibilities for precise genome editing. Single-stranded donors
26 are indeed a promising option for gene editing. We have shown that short oligonucleotides
27 (ssODN) require only short homology regions (around 35 nt), and when modified with
28 phosphorothioate linkages they can exhibit very high precise editing activity to introduce short
29 DNA sequences (<100 bp); in addition, they have the advantage to be easy to design and are
30 synthesized commercially.⁷³ To integrate longer sequences, protocols for efficient synthesis of
31 long single-stranded DNA were successfully developed and used to generate precise
32 modifications in different systems.⁷⁴ The mechanism of HDR with single-stranded donors is
33 not entirely characterized but was shown to involve factors of the Fanconi repair pathway, that
34 are shared with the HR pathway. Donor and nuclease delivery can also have a strong impact.
35 For example, AAV vectors promote efficient precise gene editing, as shown by the Porteus
36 lab⁷⁵ and further exemplified by work¹⁴ from the Amendola lab at Généthon (Evry, France).
37 This is possibly related to AAV vector sequences binding to nuclear factors favorable to HDR
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 or to differences in final nuclear concentration of donor sequences. We have also shown that
4 increased HDR genome editing can be obtained using Cas9 protein compared to mRNA.⁷⁶

5 Efficiency of precise gene modification by HDR nevertheless remains too often very limited.
6
7 Pioneer studies from D Carroll found that genetic inactivation of Ligase 4, an essential NHEJ
8 protein, increased the frequency of HDR in *Drosophila melanogaster* and therefore showed
9 that manipulating DNA repair pathways can help to increase the efficiency of precise gene
10 editing.⁷¹ Pharmacological modulators, such as DNAP-PKc inhibitor nedisertib⁷⁷, can thus
11 improve gene editing but unfortunately are associated with non-specific toxicity. Several
12 research teams, including ours, have next shown that direct fusion of DNA repair proteins to
13 Cas9 can also bias the outcome of DNA repair and be used to favor precise gene editing by
14 HDR (**Figure 3 A, B**). The potential advantage of such targeting of the repair protein of interest
15 at the DSB site is to avoid global effects on cellular DNA repair induced by pharmacological
16 inhibitors. Since processing of DSB ends via 5' to 3' resection is the major determinant of repair
17 pathway choice, CtIP, a protein that promotes Mre11 exonuclease activity at this early step of
18 HDR, was fused to Cas9. The fusion of Cas9 with a minimal N-terminal fragment of CtIP was
19 sufficient to stimulate HDR⁷⁸. This fragment contains the cell-cycle-dependent phosphorylation
20 sites of CtIP that represent one of the main control points of HDR (**Figure 3B**). Another option
21 is to perform co-targeting of a gene with a phenotype that can be conveniently screened to
22 enrich for cells carrying the modifications of interest.⁷⁹

23
24 Finally, novel tools developed by the Liu lab at MIT bypass the limited activity of HDR by
25 avoiding DSB repair and engaging other repair pathways; these tools raise exciting possibilities
26 currently being investigated. For example, base editing is achieved by fusing C or A deaminase
27 moieties to D10A Cas9 nickase (**Figure 3C**).⁸⁰ Co-targeting of a selectable gene with a base
28 editor can also be used to increase efficiency⁸¹ and such tools have been used in animals to
29 generate models of human disease, for instance cancer modelling in zebrafish⁸² by the Del Bene
30 team at the Institute for Vision. A major limitation, however, is that all target nucleotides in a
31 specific window will be modified (**Figure 3C**), limiting precision of the approach. In addition,
32 base editors can currently install only 6 (C→T, A→G, C→G, G→A, T→C, G→C) of the 12
33 possible types of point mutations. An alternative, potentially universal approach for small
34 sequence changes, point mutations, small insertions and small deletions, is prime editing. It
35 implies a fusion of the H840A Cas9 nickase to the Reverse transcriptase of the Moloney Murine
36 Leukemia Virus and modified guide RNAs carrying sequence templates to be copied into the
37 target genomic site (**Figure 3D**).⁸³ Prime editing is actively investigated to address its highly
38 variable efficiency and overcome delivery challenges. Both base editing and prime editing are
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 based on targeting an enzyme that will directly modify DNA (respectively C or A deaminase
4 or reverse transcriptase) to the target sequence of interest with the CRISPR/Cas9 system.
5
6 However, only one DNA strand is modified and stable introduction of the mutation depends on
7
8 copying the modification onto the second DNA strand. DNA repair pathways involved need to
9
10 be better understood and may also be manipulated to effectively increase gene editing
11 efficiency.
12
13

14
15 The improvement of the firstly described CRISPR/Cas genome editing system resulted in the
16 development of sophisticated novel gene editing tools with more precision and flexibility
17 genome editing reagents. From a gene therapy point of view, efforts are still needed to improve
18 editing capacities, and also to characterize and understand all the consequences of CRISPR/Cas
19 treatments, as well as to propose innovative approaches to deliver editing agents into cells, as
20 discussed below.
21
22
23
24
25

26 27 28 29 **Nanoblades for efficient non-toxic cellular delivery of the gene editing machinery into** 30 **gene therapy targets** 31

32
33
34 To obtain efficient gene editing in primary blood target cells, the delivery systems to introduce
35 the endonuclease, to produce DSB and the donor DNA for Knock-in (KI) into the nucleus of
36 the target cell, have to be very efficient. There are different methods to deliver the gene editing
37 machinery into the cells: transduction by integrating lentiviral vectors (LV), or adeno-
38 associated viral (AAV) vectors, transfection with DNA or RNA or electroporation with
39 ribonucleoprotein CAS9/gRNA complexes (RNPs) (**Figure 4A**). For HDR strategies the donor
40 template can be supplied by infection with an AAV vector, integrative deficient LV (IDLV) or
41 electroporation of single-stranded DNA or oligonucleotides encoding the template DNA. All
42 these methods have delivered the gene editing tools with different degrees of efficiency, toxicity
43 and off-target effects.
44
45
46
47
48
49
50

51
52
53 To introduce the gene editing machinery in primary cells, the method of choice at the moment
54 is electroporation of RNPs, which allows efficient editing of human T and B cells and HSPCs.⁷
55 For B cells, other methods were employed like electroporation of Cas9 mRNA or the
56 combination of Cas9 protein with chemically modified gRNA, which in combination with an
57 AAV6 vector encoding the donor template resulted in efficient KI in B cells.³ In the case of
58
59
60

1
2
3 HSPCs, Cas9 has been efficiently introduced by electroporation of CAS9/gRNA complexes
4 (RNPs).

5
6 For gene therapy strategies based on NHEJ in HSPCs, diseases such as β -hemoglobinopathies
7 (see first section), HIV or Fanconi anemia have been successfully corrected by gene editing.
8 For example in Fanconi anemia the introduction of Cas9/gRNA complexes by electroporation
9 of RNPs introduced DSBs in the mutated FANCA gene, which when repaired by NHEJ,
10 restored the FA gene function.¹³ For HDR strategies in HSPCs, the donor template is being
11 introduced preferentially using AAV6 which allowed genetic repair of multiple diseases such
12 as chronic granulomatous disease (CGD), SCID-X or WAS.⁸⁴ Although these approaches were
13 successful, some drawbacks were reported such as cell death and off-target effects.

14
15 The ideal gene editing tool should be precise, fast, non-toxic and induce as less as possible off-
16 target effects. Recently, two collaborative French teams (CIRI, Lyon, France) developed a new
17 gene editing tool delivery system, the “nanoblades”. This is a vehicle in which the Cas9/gRNA
18 RNP is packaged into a modified virus like particles (VLP) derived from a murine leukemia
19 virus (MLV) or HIV (**Figure 4B**).^{85,86} The endonuclease, Cas9, is fused to a viral structural
20 protein gag, associated with its gRNA and is by this means actively incorporated into the VLPs.
21 These nanoblades allow rapid and transient RNP delivery and importantly are devoid of viral
22 genomic sequences. They produce DSBs rapidly and efficiency in immortalized cells, iPSCs
23 and primary cells.⁸⁶ More interestingly, since nanoblades are viral-vector-derived particles
24 (VLP), they carry a viral envelope at their surface to allow VLP cell entry. They can thus easily
25 be pseudotyped as their counterpart viral vectors with different envelope glycoproteins (gps).
26 We have previously shown that the baboon endogenous virus (BaEV) envelope gp incorporated
27 into a LV, allowed efficient cell entry into human T, B and HSPCs (**Figure 4C**).^{84,87-89} Indeed,
28 nanoblades displaying at their surface a combination of BaEV and the vesicular stomatitis virus
29 G (VSV-G) envelope glycoproteins deliver the Cas9/gRNA transiently and rapidly into slightly
30 activated T, B cells and HSPCs without any change in their phenotypes nor cellular toxicity.⁸⁵

31
32 We demonstrated that nanoblades confer efficient delivery of the gene editing machinery in
33 HSPCs reaching up to 80% editing, without obvious detection of gene editing at off-target sites,
34 in contrast to other methods. Finally, treatment of HSPCs with nanoblades in combination with
35 a donor DNA template encoding rAAV6 vector resulted in up to 40 % stable expression cassette
36 knock-in into a specific gene locus (**Figure 4D**). Importantly, no toxicity was detected upon
37 nanoblade-mediated KI in HSPCs since no significant effect was seen on cell survival and
38 proliferation in nanoblade treated versus untreated cells. Different other methods to deliver the
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 gene editing tools such as electroporation, adenoviruses, AAVs and LVs have been used,
4 conferring different degrees of efficiency, toxicity, and off-target effects. The nanoblades
5 combine actually the low to undetected toxicity of retroviral delivery (VLP) and the transient
6 expression of Cas9/gRNA RNP-mediated gene editing. Indeed, nanoblades confer efficient
7 NHEJ-mediated gene editing in HSPCs and in T and B cells, but not at expense of significant
8 induced cellular toxicity.
9

10
11
12
13
14
15 Nanoblades represent an easy to use, flexible and efficient platform for gene editing in gene
16 therapy targets. Easy to use since only the plasmid coding for the gRNAs needs to be redesigned
17 to target another genomic locus. Flexible since they can harbor multiple gRNAs to permit
18 knock-out of multiple genes at once.⁸⁶ Continuously Cas9 proteins are improved to reduce off-
19 target activity or increase efficiency. For example other targetable nucleases were identified
20 e.g. Cpf1 nucleases, high fidelity Cas9, nickases, hyper-accurate Cas9^{90,91} or to increase the
21 precision of editing, base editors were engineered for therapeutic applications.⁹² All these new
22 components might readily be incorporated into nanoblades by fusing them to MLV or HIV gag
23 proteins.
24
25
26
27
28
29
30
31

32
33 In the same line, other groups have developed CRISPR/Cas9 vehicles that resemble our
34 nanoblades.⁹³⁻⁹⁵ The three systems were highly efficient for gene editing in cell lines and some
35 in primary cells such as iPSCs. However, these transient CRISPR/Cas9 delivery systems were
36 not evaluated for gene editing in human T, B and HSPCs gene therapy targets yet.
37

38
39 Summarizing, these nanoblades are simple to implement, show high flexibility for different
40 targets including primary immune cells of human and murine origin, is relatively inexpensive
41 and therefore provides important perspectives for basic and clinical translation in the area of
42 gene therapy.
43
44
45
46
47

48 **Conclusion**

49
50 Gene editing has now emerged as a realistic approach for treatment of both inherited and
51 acquired diseases. After giving an overview of some recent particular preclinical gene editing
52 applications for a variety of different diseases (e.g. hematopoietic, muscle and cancer
53 indications) developed by French researchers, we wanted to underline here that gene editing
54 has entered a new era of research focusing on improving precision, delivery and safety of these
55 tools in primary gene therapy target cells. Nevertheless, first results from clinical trials indicate
56
57
58
59
60

1
2
3 that therapeutic gene editing can be safe and might provide a therapeutic option for treatment
4 of many human diseases.
5
6
7
8

9 **Acknowledgments**

10
11
12 We thank J. Boutin, G. Cullot, F. Prat, J. Rosier and D. Cappellen, the biotherapy team
13 (Inserm U1035), Vect'Ub platform (TBM core), Bordeaux hospital genetic laboratory,
14 Bordeaux hospital tumor Biology and Tumor Bank Laboratory for their main contributions.
15
16 We thank M. Jimena A. Recalde, C. Costa, O. Bernadin, S. Périan, F. Fusil, G. Froment, F-L.
17 Cosset, E. Ricci and P. E. Mangeot (CIRI, Lyon, France) for their contributions to the
18 nanoblade work. M.A. and A.B-B. thank past and present members of their laboratory at
19 Genethon (Evry, France). We thank current and past members of the GE2R team at MNHN
20 lab (Inserm U1154/CNRS UMR7196).
21
22
23
24
25
26
27

28 **Authorship confirmation statement**

29
30
31 A.B., F.M.G. wrote the manuscript. A.M., M.A., M.L. and G.F. wrote the manuscript and
32 prepared Figure 1. J.V. wrote the manuscript and prepared figure 2. M.C., J-P.C., C.G., D.G.
33 wrote the manuscript and prepared Figure 3. EV and A.G-G. wrote the manuscript and prepared
34 Figure 4. C.S. and A.B-B. wrote the manuscript.
35
36
37
38

39 **Author(s') disclosure statement(s)**

40
41
42 A.B., F.M.G., E.V., A.G-G, M.A. A.M., G.F., M.L., M.C., J-P.C., C.G., D.G., J.F. have no
43 conflict of interest to disclose. J.V. is currently a Collectis. SA employee, TALEN® is a
44 Collectis' patented technology. A.B-B. has a patent application related to gene editing of DM1.
45 J-P. C. and C.G. have a patent application related to gene editing with Cas9 fusion to a CtIP
46 Nter domain.
47
48
49
50
51

52 **Funding statement**

53
54
55 We thank the Agence de Biomédecine, INSERM, Bordeaux University and French ministry of
56 higher education and research for financial support. We thank the EU (Euronanomed, AAV-
57 Chem), Cancéropole (CRISPR/Cas9 Screen Action) and AFM for financial support. This work
58 was supported by State funding from the Agence Nationale de la Recherche (ANR) (ANR-10-
59
60

IAHU-01, ANR-16-CE18-0012-01, ANR-II-INSB-0014, ANR-16-CE18 STaHR) and the European Research Council. This work was supported by the AFM-Telethon, Genopole (Chaire Fondagen). We thank Canceropôle Grand-Ouest et AVISAN Plan Cancer for financial support.

Figure legends

Figure 1 Editing human HSPCs as therapeutic strategy for genetic disorders. Genetics and pathophysiology of SCD **(A)** and β -thalassemia **(B)**. β^S , sickle β -globin. β^0 and β^+ indicate β -thalassemia mutations that cause absent or reduced β -globin expression, respectively. δ , δ -globin β -like chain that accounts for $\leq 3\%$ of the total β -like chains in adult RBCs. **(C)** Editing the β -globin locus to reactivate HbF expression. Dark red scissors indicate CRISPR/Cas9 nuclease editing the $G\gamma$ - and $A\gamma$ -globin promoters (edited promoters are indicated with red boxes). Yellow scissors indicate CRISPR/Cas9 nuclease generating an HPFH-like large deletion (the deleted region is indicated with a yellow box). ϵ , embryonic β -like globin gene; $G\gamma$ and $A\gamma$, fetal β -like globin gene; $\psi\beta$, β -globin pseudogene; β_{mut} , β -globin gene harboring SCD or β -thalassemia mutations. **(D)** Editing the α -globin locus to correct β -thalassemia or lysosomal storage disorders. Grey scissors indicate CRISPR/Cas9 nuclease deleting the α_2 gene, which is replaced by a therapeutic β -like globin gene or by a transgene expressing a secreted protein. ζ , embryonic α -like globin gene; $\psi\zeta$, ζ -globin pseudogene; α_1 and α_2 fetal/adult α -globin genes; β_{like} , therapeutic β -like globin gene; GoI, gene of interest; F9, Factor IX; LAL, lysosomal acid lipase; GLA, α -galactosidase; IDUA, α -L-iduronidase.

Figure 2. Genome engineering strategies used to unleash the full potential of CAR T cell therapies.

(A) Schema describing the concept of autologous CAR T-cell therapy. **(B)** Schema describing the concept of universal CAR T-cell therapy compatible with adoptive transplant in allogeneic settings. **(C)** top panel, Schema describing the concept of Graft versus Host (GvH) and Host versus graft (HvG) reactions occurring during adoptive transplant of T-cells in allogeneic settings. **(C)** bottom panel, Genome engineering approaches developed to prevent GvH and HvG. **(D)** Genome engineering approach to prevent cytokine release syndrome. **(E)** Genome engineering approach to improve CAR T-cell potency by enabling a tumor dependent secretion of the IL-12 immunostimulatory agent.

1
2
3
4
5
6
7 **Figure 3** Genome editing strategies.

8 Different classes of CRISPR-based genome editing agents are shown: nucleases, wt (**A**) or
9 fused to HDR enhancer (**B**), base editors (**C**), and prime editors (**D**). (PAM) protospacer
10 adjacent motif; (HDR) homology-directed repair; (RT): transcriptase.
11
12
13
14
15
16
17
18

19 **Figure 4.** Delivery methods for delivery of CRISPR/Cas9 into primary gene target cells

20 (**A**) Electroporation of RNP complexes, AAV6 encoding CRISPR and lentiviral vectors
21 encoding the CRISPR/Cas9 and the gRNA. (**B**) Improvement of delivery into primary cells;
22 HSC, T cells and B cells by pseudotyping with heterologous viral envelopes. Primary cells
23 express receptors such as ASCT1/2, SLAM and CD46, which allow LVs displaying envelopes
24 from the measles virus (HF) or the Baboon endogenous virus (BaEV) to deliver their cargo into
25 primary cells efficiently. However, unstimulated T, B cells and HSCs do not express the
26 receptor for the Vesicular stomatitis virus G (VSV-G) envelope, prohibiting efficient
27 transduction in non-stimulated cells. (**C**) Schematic representation of nanoblades and its
28 components. (**D**) HDR repair using CRISPR/Cas9 introduced by nanoblades and a donor DNA
29 template. The donor template is provided into the cell by an AAV6 vector, CRISPR/Cas9 RNP
30 delivered by nanoblades make a DSB and the homology arms in the donor DNA allow
31 homology recombination introducing a transgene into the cell genome in a specific gene locus.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Doudna, J.A. & Charpentier, E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. *Science* (2014); 346, 1258096.
2. Antony, J.S., Latifi, N., Haque, A. et al. Gene correction of HBB mutations in CD34(+) hematopoietic stem cells using Cas9 mRNA and ssODN donors. *Mol Cell Pediatr* (2018); 5, 9.
3. Hendel, A., Bak, R.O., Clark, J.T. et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. *Nat Biotechnol* (2015); 33, 985-989.
4. Hartweger, H., McGuire, A.T., Horning, M. et al. HIV-specific humoral immune responses by CRISPR/Cas9-edited B cells. *J Exp Med* (2019); 216, 1301-1310.
5. Heckl, D., Kowalczyk, M.S., Yudovich, D. et al. Generation of mouse models of myeloid malignancy with combinatorial genetic lesions using CRISPR-Cas9 genome editing. *Nat Biotechnol* (2014); 32, 941-946.
6. Mandal, P.K., Ferreira, L.M., Collins, R. et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. *Cell Stem Cell* (2014); 15, 643-652.
7. Hultquist, J.F., Hiatt, J., Schumann, K. et al. CRISPR-Cas9 genome engineering of primary CD4(+) T cells for the interrogation of HIV-host factor interactions. *Nat Protoc* (2019); 14, 1-27.
8. Pavani, G., Fabiano, A., Laurent, M. et al. Correction of beta-thalassemia by CRISPR/Cas9 editing of the alpha-globin locus in human hematopoietic stem cells. *Blood Adv* (2021); 5, 1137-1153.
9. Gentner, B. & Naldini, L. In Vivo Selection for Gene-Corrected HSPCs Advances Gene Therapy for a Rare Stem Cell Disease. *Cell Stem Cell* (2019); 25, 592-593.
10. Kuo, C.Y., Long, J.D., Campo-Fernandez, B. et al. Site-Specific Gene Editing of Human Hematopoietic Stem Cells for X-Linked Hyper-IgM Syndrome. *Cell Rep* (2018); 23, 2606-2616.
11. Koniali, L., Lederer, C.W. & Kleanthous, M. Therapy Development by Genome Editing of Hematopoietic Stem Cells. *Cells* (2021); 10.
12. Verhoeyen, E., Roman-Rodriguez, F.J., Cosset, F.L., Levy, C. & Rio, P. Gene Therapy in Fanconi Anemia: A Matter of Time, Safety and Gene Transfer Tool Efficiency. *Curr Gene Ther* (2017); 16, 297-308.
13. Roman-Rodriguez, F.J., Ugalde, L., Alvarez, L. et al. NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia. *Cell Stem Cell* (2019); 25, 607-621 e607.
14. Pavani, G., Laurent, M., Fabiano, A. et al. Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins. *Nat Commun* (2020); 11, 3778.
15. Antoniani, C., Meneghini, V., Lattanzi, A. et al. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human beta-globin locus. *Blood* (2018); 131, 1960-1973.
16. Martyn, G.E., Wienert, B., Yang, L. et al. Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding. *Nat Genet* (2018); 50, 498-503.
17. Mhaidly, R. & Verhoeyen, E. Humanized Mice Are Precious Tools for Preclinical Evaluation of CAR T and CAR NK Cell Therapies. *Cancers (Basel)* (2020); 12.
18. Ren, J., Liu, X., Fang, C. et al. Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition. *Clin Cancer Res* (2017); 23, 2255-2266.
19. Lo Scudato, M., Poulard, K., Sourd, C. et al. Genome Editing of Expanded CTG Repeats within the Human DMPK Gene Reduces Nuclear RNA Foci in the Muscle of DM1 Mice. *Mol Ther* (2019); 27, 1372-1388.

20. Naeem, M., Majeed, S., Hoque, M.Z. & Ahmad, I. Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing. *Cells* (2020); 9.
21. Bao, X.R., Pan, Y., Lee, C.M., Davis, T.H. & Bao, G. Tools for experimental and computational analyses of off-target editing by programmable nucleases. *Nat Protoc* (2021); 16, 10-26.
22. Adikusuma, F., Piltz, S., Corbett, M.A. et al. Large deletions induced by Cas9 cleavage. *Nature* (2018); 560, E8-E9.
23. Choi, P.S. & Meyerson, M. Targeted genomic rearrangements using CRISPR/Cas technology. *Nat Commun* (2014); 5, 3728.
24. De Ravin, S.S., Li, L., Wu, X. et al. CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease. *Sci Transl Med* (2017); 9.
25. Forget, B.G. Molecular basis of hereditary persistence of fetal hemoglobin. *Ann N Y Acad Sci* (1998); 850, 38-44.
26. Lattanzi, A., Meneghini, V., Pavani, G. et al. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements. *Mol Ther* (2019); 27, 137-150.
27. Weber, L., Frati, G., Felix, T. et al. Editing a gamma-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype. *Sci Adv* (2020); 6.
28. Mettananda, S., Gibbons, R.J. & Higgs, D.R. alpha-Globin as a molecular target in the treatment of beta-thalassemia. *Blood* (2015); 125, 3694-3701.
29. Mettananda, S., Fisher, C.A., Hay, D. et al. Editing an alpha-globin enhancer in primary human hematopoietic stem cells as a treatment for beta-thalassemia. *Nat Commun* (2017); 8, 424.
30. Cromer, M.K., Camarena, J., Martin, R.M. et al. Gene replacement of alpha-globin with beta-globin restores hemoglobin balance in beta-thalassemia-derived hematopoietic stem and progenitor cells. *Nat Med* (2021); 27, 677-687.
31. Biffi, A. Hematopoietic Stem Cell Gene Therapy for Storage Disease: Current and New Indications. *Mol Ther* (2017); 25, 1155-1162.
32. Gorzelany, J.A. & de Souza, M.P. Protein replacement therapies for rare diseases: a breeze for regulatory approval? *Sci Transl Med* (2013); 5, 178fs110.
33. Pavani, G. & Amendola, M. Targeted Gene Delivery: Where to Land. *Frontiers in Genome Editing* (2021); 2.
34. Depienne, C. & Mandel, J.L. 30 years of repeat expansion disorders: What have we learned and what are the remaining challenges? *Am J Hum Genet* (2021); 108, 764-785.
35. Babacic, H., Mehta, A., Merkel, O. & Schoser, B. CRISPR-cas gene-editing as plausible treatment of neuromuscular and nucleotide-repeat-expansion diseases: A systematic review. *PLoS One* (2019); 14, e0212198.
36. Mahadevan, M., Tsilfidis, C., Sabourin, L. et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. *Science* (1992); 255, 1253-1255.
37. De Antonio, M., Dogan, C., Hamroun, D. et al. Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification. *Rev Neurol (Paris)* (2016); 172, 572-580.
38. Braz, S.O., Acquaire, J., Gourdon, G. & Gomes-Pereira, M. Of Mice and Men: Advances in the Understanding of Neuromuscular Aspects of Myotonic Dystrophy. *Front Neurol* (2018); 9, 519.
39. Gao, Y., Guo, X., Santostefano, K. et al. Genome Therapy of Myotonic Dystrophy Type 1 iPS Cells for Development of Autologous Stem Cell Therapy. *Mol Ther* (2016); 24, 1378-1387.

- 1
- 2
- 3 40. Richard, G.F. Shortening trinucleotide repeats using highly specific endonucleases: a
- 4 possible approach to gene therapy? *Trends Genet* (2015); 31, 177-186.
- 5 41. Cinesi, C., Aeschbach, L., Yang, B. & Dion, V. Contracting CAG/CTG repeats using
- 6 the CRISPR-Cas9 nickase. *Nat Commun* (2016); 7, 13272.
- 7 42. Batra, R., Nelles, D.A., Roth, D.M. et al. The sustained expression of Cas9 targeting
- 8 toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy type 1. *Nat*
- 9 *Biomed Eng* (2021); 5, 157-168.
- 10 43. Dastidar, S., Ardui, S., Singh, K. et al. Efficient CRISPR/Cas9-mediated editing of
- 11 trinucleotide repeat expansion in myotonic dystrophy patient-derived iPS and myogenic cells.
- 12 *Nucleic Acids Res* (2018); 46, 8275-8298.
- 13 44. Provenzano, C., Cappella, M., Valaperta, R. et al. CRISPR/Cas9-Mediated Deletion of
- 14 CTG Expansions Recovers Normal Phenotype in Myogenic Cells Derived from Myotonic
- 15 Dystrophy 1 Patients. *Mol Ther Nucleic Acids* (2017); 9, 337-348.
- 16 45. van Agtmaal, E.L., Andre, L.M., Willemse, M. et al. CRISPR/Cas9-Induced
- 17 (CTGCAG)_n Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for
- 18 Therapeutic Genome Editing. *Mol Ther* (2017); 25, 24-43.
- 19 46. Zhang, N., Bewick, B., Xia, G., Furling, D. & Ashizawa, T. A CRISPR-Cas13a Based
- 20 Strategy That Tracks and Degrades Toxic RNA in Myotonic Dystrophy Type 1. *Front Genet*
- 21 (2020); 11, 594576.
- 22 47. Gill, S. & Brudno, J.N. CAR T-Cell Therapy in Hematologic Malignancies: Clinical
- 23 Role, Toxicity, and Unanswered Questions. *Am Soc Clin Oncol Educ Book* (2021); 41, 1-20.
- 24 48. Anagnostou, T., Riaz, I.B., Hashmi, S.K., Murad, M.H. & Kenderian, S.S. Anti-CD19
- 25 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review
- 26 and meta-analysis. *Lancet Haematol* (2020); 7, e816-e826.
- 27 49. Mullard, A. FDA approves fourth CAR-T cell therapy. *Nat Rev Drug Discov* (2021);
- 28 20, 166.
- 29 50. Shah, B.D., Ghobadi, A., Oluwole, O.O. et al. KTE-X19 for relapsed or refractory adult
- 30 B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre
- 31 ZUMA-3 study. *Lancet* (2021).
- 32 51. Fajgenbaum, D.C. & June, C.H. Cytokine Storm. *N Engl J Med* (2020); 383, 2255-2273.
- 33 52. Poirot, L., Philip, B., Schiffer-Mannioui, C. et al. Multiplex Genome-Edited T-cell
- 34 Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. *Cancer Res*
- 35 (2015); 75, 3853-3864.
- 36 53. Benjamin, R., Graham, C., Yallop, D. et al. Genome-edited, donor-derived allogeneic
- 37 anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic
- 38 leukaemia: results of two phase 1 studies. *Lancet* (2020); 396, 1885-1894.
- 39 54. Valton, J., Guyot, V., Marechal, A. et al. A Multidrug-resistant Engineered CAR T Cell
- 40 for Allogeneic Combination Immunotherapy. *Mol Ther* (2015); 23, 1507-1518.
- 41 55. Giavridis, T., van der Stegen, S.J.C., Eyquem, J. et al. CAR T cell-induced cytokine
- 42 release syndrome is mediated by macrophages and abated by IL-1 blockade. *Nat Med* (2018);
- 43 24, 731-738.
- 44 56. Sterner, R.M., Sakemura, R., Cox, M.J. et al. GM-CSF inhibition reduces cytokine
- 45 release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.
- 46 *Blood* (2019); 133, 697-709.
- 47 57. Yi, Y., Chai, X., Zheng, L. et al. CRISPR-edited CART with GM-CSF knockout and
- 48 auto secretion of IL6 and IL1 blockers in patients with hematologic malignancy. *Cell Discov*
- 49 (2021); 7, 27.
- 50 58. Sachdeva, M., Busser, B.W., Temburni, S. et al. Repurposing endogenous immune
- 51 pathways to tailor and control chimeric antigen receptor T cell functionality. *Nat Commun*
- 52 (2019); 10, 5100.
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60

59. Zhang, L., Morgan, R.A., Beane, J.D. et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. *Clin Cancer Res* (2015); 21, 2278-2288.
60. Cullot, G., Boutin, J., Toutain, J. et al. CRISPR-Cas9 genome editing induces megabase-scale chromosomal truncations. *Nat Commun* (2019); 10, 1136.
61. Prat, F., Toutain, J., Boutin, J. et al. Mutation-Specific Guide RNA for Compound Heterozygous Porphyria On-target Scarless Correction by CRISPR/Cas9 in Stem Cells. *Stem Cell Reports* (2020); 15, 677-693.
62. Sledzinski, P., Dabrowska, M., Nowaczyk, M. & Olejniczak, M. Paving the way towards precise and safe CRISPR genome editing. *Biotechnol Adv* (2021); 49, 107737.
63. Shin, H.Y., Wang, C., Lee, H.K. et al. CRISPR/Cas9 targeting events cause complex deletions and insertions at 17 sites in the mouse genome. *Nat Commun* (2017); 8, 15464.
64. Korablev, A., Lukyanchikova, V., Serova, I. & Battulin, N. On-Target CRISPR/Cas9 Activity Can Cause Undesigned Large Deletion in Mouse Zygotes. *Int J Mol Sci* (2020); 21.
65. Weisheit, I., Kroeger, J.A., Malik, R. et al. Detection of Deleterious On-Target Effects after HDR-Mediated CRISPR Editing. *Cell Rep* (2020); 31, 107689.
66. Zuccaro, M.V., Xu, J., Mitchell, C. et al. Allele-Specific Chromosome Removal after Cas9 Cleavage in Human Embryos. *Cell* (2020); 183, 1650-1664 e1615.
67. Leibowitz, M.L., Papatheanasiou, S., Doerfler, P.A. et al. Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing. *Nat Genet* (2021); 53, 895-905.
68. Javidi-Parsijani, P., Lyu, P., Makani, V. et al. CRISPR/Cas9 increases mitotic gene conversion in human cells. *Gene Ther* (2020); 27, 281-296.
69. Mosbach, V., Poggi, L. & Richard, G.F. Trinucleotide repeat instability during double-strand break repair: from mechanisms to gene therapy. *Curr Genet* (2019); 65, 17-28.
70. Chouluka, A., Perrin, A., Dujon, B. & Nicolas, J.F. Induction of homologous recombination in mammalian chromosomes by using the I-SceI system of *Saccharomyces cerevisiae*. *Mol Cell Biol* (1995); 15, 1968-1973.
71. Yeh, C.D., Richardson, C.D. & Corn, J.E. Advances in genome editing through control of DNA repair pathways. *Nat Cell Biol* (2019); 21, 1468-1478.
72. Wienert, B., Nguyen, D.N., Guenther, A. et al. Timed inhibition of CDC7 increases CRISPR-Cas9 mediated templated repair. *Nat Commun* (2020); 11, 2109.
73. Renaud, J.B., Boix, C., Charpentier, M. et al. Improved Genome Editing Efficiency and Flexibility Using Modified Oligonucleotides with TALEN and CRISPR-Cas9 Nucleases. *Cell Rep* (2016); 14, 2263-2272.
74. Quadros, R.M., Miura, H., Harms, D.W. et al. Easi-CRISPR: a robust method for one-step generation of mice carrying conditional and insertion alleles using long ssDNA donors and CRISPR ribonucleoproteins. *Genome Biol* (2017); 18, 92.
75. Bak, R.O. & Porteus, M.H. CRISPR-Mediated Integration of Large Gene Cassettes Using AAV Donor Vectors. *Cell Rep* (2017); 20, 750-756.
76. Menoret, S., De Cian, A., Tesson, L. et al. Homology-directed repair in rodent zygotes using Cas9 and TALEN engineered proteins. *Sci Rep* (2015); 5, 14410.
77. Riesenberger, S., Chintalapati, M., Macak, D. et al. Simultaneous precise editing of multiple genes in human cells. *Nucleic Acids Res* (2019); 47, e116.
78. Charpentier, M., Khedher, A.H.Y., Menoret, S. et al. CtIP fusion to Cas9 enhances transgene integration by homology-dependent repair. *Nat Commun* (2018); 9, 1133.
79. Agudelo, D., Durringer, A., Bozoyan, L. et al. Marker-free coselection for CRISPR-driven genome editing in human cells. *Nat Methods* (2017); 14, 615-620.
80. Rees, H.A. & Liu, D.R. Base editing: precision chemistry on the genome and transcriptome of living cells. *Nat Rev Genet* (2018); 19, 770-788.

- 1
2
3 81. Billon, P., Bryant, E.E., Joseph, S.A. et al. CRISPR-Mediated Base Editing Enables
4 Efficient Disruption of Eukaryotic Genes through Induction of STOP Codons. *Mol Cell* (2017);
5 67, 1068-1079 e1064.
6
7 82. Rosello, M., Voungny, J., Czarny, F. et al. Precise base editing for the in vivo study of
8 developmental signaling and human pathologies in zebrafish. *Elife* (2021); 10.
9 83. Anzalone, A.V., Randolph, P.B., Davis, J.R. et al. Search-and-replace genome editing
10 without double-strand breaks or donor DNA. *Nature* (2019); 576, 149-157.
11 84. Gutierrez-Guerrero, A., Cosset, F.L. & Verhoeven, E. Lentiviral Vector Pseudotypes:
12 Precious Tools to Improve Gene Modification of Hematopoietic Cells for Research and Gene
13 Therapy. *Viruses* (2020); 12.
14 85. Gutierrez-Guerrero, A., Abrey Recalde, M.J., Mangeot, P.E. et al. Baboon Envelope
15 Pseudotyped “Nanoblades” Carrying Cas9/gRNA Complexes Allow Efficient Genome Editing
16 in Human T, B, and CD34+ Cells and Knock-in of AAV6-Encoded Donor DNA in CD34+
17 Cells. *Frontiers in Genome Editing* (2021); 3.
18 86. Mangeot, P.E., Risson, V., Fusil, F. et al. Genome editing in primary cells and in vivo
19 using viral-derived Nanoblades loaded with Cas9-sgRNA ribonucleoproteins. *Nat Commun*
20 (2019); 10, 45.
21 87. Bernadin, O., Amirache, F., Girard-Gagnepain, A. et al. Baboon envelope LVs
22 efficiently transduced human adult, fetal, and progenitor T cells and corrected SCID-X1 T-cell
23 deficiency. *Blood Adv* (2019); 3, 461-475.
24 88. Girard-Gagnepain, A., Amirache, F., Costa, C. et al. Baboon envelope pseudotyped LVs
25 outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs.
26 *Blood* (2014); 124, 1221-1231.
27 89. Levy, C., Amirache, F., Girard-Gagnepain, A. et al. Measles virus envelope
28 pseudotyped lentiviral vectors transduce quiescent human HSCs at an efficiency without
29 precedent. *Blood Adv* (2017); 1, 2088-2104.
30 90. Kleinstiver, B.P., Pattanayak, V., Prew, M.S. et al. High-fidelity CRISPR-Cas9
31 nucleases with no detectable genome-wide off-target effects. *Nature* (2016); 529, 490-495.
32 91. Vakulskas, C.A., Dever, D.P., Rettig, G.R. et al. A high-fidelity Cas9 mutant delivered
33 as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and
34 progenitor cells. *Nat Med* (2018); 24, 1216-1224.
35 92. Osborn, M.J., Newby, G.A., McElroy, A.N. et al. Base Editor Correction of COL7A1
36 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs. *J Invest*
37 *Dermatol* (2020); 140, 338-347 e335.
38 93. Gee, P., Lung, M.S.Y., Okuzaki, Y. et al. Extracellular nanovesicles for packaging of
39 CRISPR-Cas9 protein and sgRNA to induce therapeutic exon skipping. *Nat Commun* (2020);
40 11, 1334.
41 94. Indikova, I. & Indik, S. Highly efficient 'hit-and-run' genome editing with
42 unconcentrated lentivectors carrying Vpr.Prot.Cas9 protein produced from RRE-containing
43 transcripts. *Nucleic Acids Res* (2020); 48, 8178-8187.
44 95. Knopp, Y., Geis, F.K., Heckl, D. et al. Transient Retrovirus-Based CRISPR/Cas9 All-
45 in-One Particles for Efficient, Targeted Gene Knockout. *Mol Ther Nucleic Acids* (2018); 13,
46 256-274.
47
48
49
50
51
52
53

Publication in press

54
55
56 CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity
57 in hematopoietic cells Boutin J, Rosier J et al Accepted July 2021, Nature communication
58
59
60




Figure 1

209x297mm (300 x 300 DPI)




Figure 2

209x297mm (300 x 300 DPI)




Figure 3

209x297mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 4

190x275mm (300 x 300 DPI)